Core Viewpoint - The announcement highlights a strategic partnership between the company’s subsidiary, Nona Bio, and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Nona Bio has entered into a non-exclusive licensing agreement with Pfizer, granting Pfizer global rights to utilize Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Bio will receive an upfront payment and is entitled to receive regulatory, clinical, and commercial milestone payments as part of the agreement [1] Group 2: Collaboration Aspects - The collaboration allows Nona Bio to work with Pfizer, leveraging its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - The announcement highlights a non-exclusive licensing agreement between Nona Bio, a wholly-owned subsidiary of HAPO (02142), and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Pfizer will gain global rights to utilize Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Bio will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Bio to leverage its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142.HK), has entered into a non-exclusive licensing agreement with Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Heptagon's wholly-owned subsidiary, Nona Biotech (Suzhou) Co., Ltd., will provide Pfizer with global access to its proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Biotech will receive an upfront payment and is entitled to receive regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Biotech to utilize its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]